Autopsy report · NCT06495307

RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

“Efficacy signal substantial enough to more to larger study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 1 month before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Lubris Bio Pty Ltd

Sponsor type

Industry

Conditions

Ocular Graft-versus-host Disease

Interventions

rhPRG4

Participants

3

Sites

2

Countries

Australia

Trials that died the same way

• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
  “early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints” (63% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (62% match in meaning)
• Apremilast in the Treatment of Uveitis
  “Investigator discretion due to lack of efficacy in three subjects enrolled” (61% match in meaning)
• A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
  “study intervention was approved by the FDA” (59% match in meaning)
• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
  “Lack of efficacy” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.